TreeFrog Therapeutics
CompanyFranceFounded 2018
TreeFrog Therapeutics develops 4 assets, the furthest preclinical (TFG-001 in Parkinson's disease). Mostly cell therapy and device; based in France, founded in 2018.
- 4
- Assets
- Furthest stage
- Preclinical
- Raised
- US$75m + €30m
- 0
- Trials
- 0
- Signals
Pipeline
4Transplanted 3D dopaminergic neurons and progenitors integrate into host tissue and restore neural connections.
Preclinical, Cell therapy, Parkinson's disease
Preclinical, Cell therapy
Monitors cell amplification and characterization through standardized 3D imaging.
Stage not known, Device
1 more asset
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Funding rounds and grants2
- People13
- Similar companies6